231 related articles for article (PubMed ID: 10773965)
1. Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis.
Clézardin P; Gligorov J; Delmas P
Joint Bone Spine; 2000 Jan; 67(1):22-9. PubMed ID: 10773965
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates in the treatment of malignant bone disease.
Berenson JR; Lipton A
Annu Rev Med; 1999; 50():237-48. PubMed ID: 10073275
[TBL] [Abstract][Full Text] [Related]
3. [Bone targeting agents: bisphosphonates].
Debiais F
Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
[TBL] [Abstract][Full Text] [Related]
4. [Osteolytic metastases of breast cancer and biphosphonates].
Lortholary A; Alleaume C; Pein F; Larra F
Rev Med Interne; 1992; 13(3):238-42. PubMed ID: 1410908
[TBL] [Abstract][Full Text] [Related]
5. Rationale for the use of bisphosphonates in bone metastases.
Kanis JA; McCloskey EV; Taube T; O'Rourke N
Bone; 1991; 12 Suppl 1():S13-8. PubMed ID: 1954047
[TBL] [Abstract][Full Text] [Related]
6. [Bisphosphonates in the treatment of multiple myeloma].
Stajszczyk M
Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
[TBL] [Abstract][Full Text] [Related]
7. [Biosphonates in oncology].
Paule B; Clerc D; Brion N
Presse Med; 2000 Apr; 29(13):723-9. PubMed ID: 10797827
[TBL] [Abstract][Full Text] [Related]
8. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
9. [The role of bisphosphonates of adjuvant therapy in breast cancer].
Gálvez-Muñoz E; Rodríguez-Lescure Á
Med Clin (Barc); 2010 Jun; 135(2):70-4. PubMed ID: 20022069
[TBL] [Abstract][Full Text] [Related]
10. Bone metastases and tumor-induced hypercalcemia.
Body JJ
Curr Opin Oncol; 1992 Aug; 4(4):624-31. PubMed ID: 1511019
[TBL] [Abstract][Full Text] [Related]
11. Use of bisphosphonates in cancer patients.
Body JJ; Coleman RE; Piccart M
Cancer Treat Rev; 1996 Jul; 22(4):265-87. PubMed ID: 9025784
[No Abstract] [Full Text] [Related]
12. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate treatment of lytic bone metastases.
Lipton A; Berenson JR
Drugs Aging; 1999 Apr; 14(4):241-6. PubMed ID: 10319239
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
15. The potential role of bisphosphonates in prostate cancer.
Oades GM; Coxon J; Colston KW
Prostate Cancer Prostatic Dis; 2002; 5(4):264-72. PubMed ID: 12627210
[TBL] [Abstract][Full Text] [Related]
16. [Action of bisphosphonates on malignant osteolysis].
Alexandre C
Presse Med; 1999 Sep; 28(28):1536-40. PubMed ID: 10526564
[TBL] [Abstract][Full Text] [Related]
17. Use of bisphosphonates in patients with metastatic bone disease.
Berenson JR; Lipton A
Oncology (Williston Park); 1998 Nov; 12(11):1573-9; discussion 1579-81. PubMed ID: 9834935
[TBL] [Abstract][Full Text] [Related]
18. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Coleman RE
Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
[TBL] [Abstract][Full Text] [Related]
19. Rationale for the use of bisphosphonates in breast cancer.
Kanis JA
Acta Oncol; 1996; 35 Suppl 5():61-7. PubMed ID: 9142969
[TBL] [Abstract][Full Text] [Related]
20. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.
Ashcroft AJ; Davies FE; Morgan GJ
Lancet Oncol; 2003 May; 4(5):284-92. PubMed ID: 12732166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
